guest ::
| Home > Publications database > Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. > print |
| Home > Publications database > Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. > print |
| 001 | 127445 | ||
| 005 | 20240228140928.0 | ||
| 024 | 7 | _ | |a 10.1016/j.tiv.2014.12.019 |2 doi |
| 024 | 7 | _ | |a pmid:25572481 |2 pmid |
| 024 | 7 | _ | |a 0887-2333 |2 ISSN |
| 024 | 7 | _ | |a 1879-3177 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2017-03468 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Savary, Camille C |b 0 |
| 245 | _ | _ | |a Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2015 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1521711922_2108 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Previous works have shown that differentiated human HepaRG cells can exhibit drug metabolism activities close to those of primary human hepatocytes for several weeks at confluence. The present study was designed to evaluate their long-term functional stability and their response to repeated daily drug treatments over a 14-day period, using a transcriptomic approach. Our data show that less than 1% of the expressed genes were markedly deregulated over this two weeks period and mainly included down-regulation of genes related to the cell cycle and from 3 days, overexpression of genes involved in xenobiotic and lipid metabolism. After daily treatment with the three PPAR agonists, fenofibrate, troglitazone and rosiglitazone qualitative and/or quantitative changes in gene profiling were observed depending on the compound and duration of treatment. The highest increase in the number of deregulated genes as a function of drug treatment was seen with rosiglitazone. The most up-regulated genes common across the three compounds were mainly related to lipid and xenobiotic metabolisms. All the data support the conclusion that human HepaRG cells have an exceptional functional stability at confluence and that they are suitable for investigations on chronic effects of drugs and other chemicals. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Chromans |2 NLM Chemicals |
| 650 | _ | 7 | |a Hypoglycemic Agents |2 NLM Chemicals |
| 650 | _ | 7 | |a Hypolipidemic Agents |2 NLM Chemicals |
| 650 | _ | 7 | |a Peroxisome Proliferator-Activated Receptors |2 NLM Chemicals |
| 650 | _ | 7 | |a Thiazolidinediones |2 NLM Chemicals |
| 650 | _ | 7 | |a rosiglitazone |0 05V02F2KDG |2 NLM Chemicals |
| 650 | _ | 7 | |a troglitazone |0 I66ZZ0ZN0E |2 NLM Chemicals |
| 650 | _ | 7 | |a Fenofibrate |0 U202363UOS |2 NLM Chemicals |
| 700 | 1 | _ | |a Jiang, Xiaoqi |0 P:(DE-He78)079436c5442874052d541943e53145ef |b 1 |u dkfz |
| 700 | 1 | _ | |a Aubry, Marc |b 2 |
| 700 | 1 | _ | |a Jossé, Rozenn |b 3 |
| 700 | 1 | _ | |a Kopp-Schneider, Annette |0 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |b 4 |u dkfz |
| 700 | 1 | _ | |a Hewitt, Philip |b 5 |
| 700 | 1 | _ | |a Guillouzo, André |b 6 |
| 773 | _ | _ | |a 10.1016/j.tiv.2014.12.019 |g Vol. 30, no. 1 Pt A, p. 27 - 35 |0 PERI:(DE-600)1501079-x |n 1 Pt A |p 27 - 35 |t Toxicology in vitro |v 30 |y 2015 |x 0887-2333 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:127445 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)079436c5442874052d541943e53145ef |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b TOXICOL IN VITRO : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|